Top

Published in:

Open Access 01-12-2021 | Correction

Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer

Authors: Jihui Chen, Zhipeng Wang, Shouhong Gao, Kejin Wu, Fang Bai, Qiqiang Zhang, Hongyu Wang, Qin Ye, Fengjing Xu, Hong Sun, Yunshu Lu, Yan Liu

Published in: Cancer Cell International | Issue 1/2021

Excerpt

Following publication of the original article [1], we were notified that the email address of Yan Liu should show before the one of Yunshu Lu. …

Chen J, Wang Z, Gao S, Wu K, Bai F, Zhang Q, Wang H, Ye Q, Xu F, Sun H, Lu Y, Liu Y. Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer. Cancer Cell Int. 2021;21:136. https://doi.org/10.1186/s12935-021-01842-x.CrossRefPubMedPubMedCentral

Title: Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
Authors: Jihui Chen
Zhipeng Wang
Shouhong Gao
Kejin Wu
Fang Bai
Qiqiang Zhang
Hongyu Wang
Qin Ye
Fengjing Xu
Hong Sun
Yunshu Lu
Yan Liu
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-01876-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

CDCA8 as an independent predictor for a poor prognosis in liver cancer

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells

Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma

Retraction Note to: miR-484 suppresses proliferation and epithelial–mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells

NK cell upraise in the dark world of cancer stem cells

Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling

Keynote webinar | Spotlight on antibody–drug conjugates in cancer